Section: Aquatic Bacteria

Streptococcosis in Farmed Fish: Pathogenesis, Diagnosis, and Vaccine Development

Introduction

Streptococcosis is a major bacterial disease affecting intensively cultured freshwater and marine fish worldwide. The primary etiological agents are Gram-positive cocci belonging to the genus Streptococcus, with Streptococcus iniae and Streptococcus agalactiae (Lancefield group B) being the most significant in tilapia (Oreochromis spp.) and rainbow trout (Oncorhynchus mykiss). Other species such as Streptococcus dysgalactiae and Streptococcus parauberis are also reported but with lower prevalence [1, 2]. The disease causes substantial economic losses due to high mortality, reduced growth, and treatment costs. This article provides an exhaustive review of the pathogenesis, diagnostic approaches, and vaccine development strategies for streptococcosis, with emphasis on the two dominant species.

Pathogenesis

Virulence Factors of Streptococcus iniae and S. agalactiae

Both species possess a polysaccharide capsule that inhibits phagocytosis and complement-mediated opsonization [3, 4]. The capsule is a critical virulence determinant; acapsular mutants are avirulent in fish models [5]. Additional virulence factors include:

  • Streptolysin S (SLS): A cytolytic toxin that damages host cell membranes and facilitates tissue invasion [6].
  • C5a peptidase: Degrades the host complement component C5a, reducing neutrophil chemotaxis [7].
  • M-like surface proteins: Bind fibrinogen and inhibit phagocytosis [8].
  • Hyaluronidase: Degrades hyaluronic acid in connective tissues, promoting bacterial dissemination [9].
  • Superoxide dismutase (SodA): Neutralizes reactive oxygen species produced by host phagocytes [10].

In S. agalactiae, the presence of the pilus island (PI) genes encoding adhesive pili is associated with adherence to fish epithelial cells and biofilm formation [11]. S. iniae produces a polysaccharide deacetylase that modifies its own capsule to evade host lectin pathways [12].

Host-Pathogen Interactions

Infection typically occurs through the gills, skin abrasions, or the gastrointestinal tract following ingestion of contaminated feed or water [13]. Bacteria adhere to mucosal surfaces using surface adhesins and then translocate into the bloodstream, causing a septicemic phase. The bacteria cross the blood-brain barrier via transcytosis or paracellular routes, leading to meningoencephalitis [14]. In tilapia, S. agalactiae serotype Ia is highly neurotropic, while serotype III is more associated with systemic disease [15].

The host immune response involves both innate and adaptive components. Teleost fish produce IgM, IgD, and IgT antibodies. However, S. iniae can modulate the host response by inducing apoptosis of head kidney macrophages and suppressing the respiratory burst [16]. Pro-inflammatory cytokines such as IL-1β, TNF-α, and IL-8 are upregulated during acute infection, contributing to tissue pathology [17].

Clinical Signs

Clinical manifestations vary with fish species, age, water temperature, and bacterial strain. Common signs include:

  • Neurological signs: Erratic swimming, spiraling, corkscrew motion, and lethargy due to meningoencephalitis [18].
  • Ocular signs: Unilateral or bilateral exophthalmia (pop-eye), corneal opacity, and intraocular hemorrhage [19].
  • Cutaneous signs: Petechial hemorrhages on the skin, fins, and opercula; ulcerative lesions; and darkening of the body [20].
  • Visceral signs: Enlarged spleen and kidney, ascites, and pericarditis [21].

Mortality rates can exceed 50% in untreated outbreaks, particularly when water temperatures rise above 25°C for S. agalactiae in tilapia [22]. Chronic infections may present with low-grade mortality and stunted growth.

Diagnosis

Bacteriological Culture

Isolation of Streptococcus spp. from brain, kidney, or spleen tissue is the gold standard. Samples are streaked onto blood agar (sheep or horse blood) or selective media such as modified Edwards medium and incubated at 25-30°C for 24-48 hours [23]. Colonies are small, grayish, and alpha-hemolytic (partial hemolysis) for S. iniae and beta-hemolytic for S. agalactiae [24]. Gram staining reveals Gram-positive cocci in chains. Biochemical identification using commercial kits (e.g., API 20 Strep) can differentiate species but may misidentify some fish isolates [25].

Molecular Diagnostics

Polymerase chain reaction (PCR) targeting species-specific genes provides rapid and sensitive detection. Common targets include:

  • S. iniae: 16S rRNA gene, lactate oxidase (lctO) gene, or the sagA gene encoding streptolysin S [26, 27].
  • S. agalactiae: cfb gene (CAMP factor), sip gene (surface immunogenic protein), or the dltS gene [28, 29].

Multiplex PCR assays can simultaneously detect S. iniae, S. agalactiae, and Lactococcus garvieae in a single reaction [30]. Real-time quantitative PCR (qPCR) allows quantification of bacterial load in tissues and water samples [31]. Loop-mediated isothermal amplification (LAMP) assays have been developed for field-deployable detection [32].

Serological Methods

Enzyme-linked immunosorbent assay (ELISA) can detect antibodies against S. agalactiae in fish serum, but seroconversion is slow and not always protective [33]. Antigen-capture ELISA using monoclonal antibodies against the capsular polysaccharide has been used for direct detection in tissue homogenates [34]. For a detailed discussion of ELISA principles, see the article on Enzyme-Linked Immunosorbent Assay (ELISA) for Feline Leukemia Virus.

Diagnostic Workflow

The following Mermaid diagram outlines a recommended diagnostic algorithm for suspected streptococcosis outbreaks.

flowchart TD
    A[Fish with clinical signs: exophthalmia, erratic swimming, hemorrhages], > B{Collect samples: brain, kidney, spleen}
    B, > C[Gram stain: Gram-positive cocci in chains]
    C, > D[Culture on blood agar at 25-30°C for 24-48h]
    D, > E{Alpha-hemolytic?}
    E, >|Yes| F[Suspected S. iniae]
    E, >|No| G[Beta-hemolytic?]
    G, >|Yes| H[Suspected S. agalactiae]
    G, >|No| I[Other Streptococcus spp. or Lactococcus]
    F, > J[PCR for lctO or 16S rRNA]
    H, > K[PCR for cfb or sip]
    I, > L[16S rRNA sequencing]
    J, > M{Positive?}
    K, > M
    L, > M
    M, >|Yes| N[Confirm diagnosis]
    M, >|No| O[Consider other pathogens: Lactococcus garvieae, Aeromonas hydrophila]
    N, > P[Antimicrobial susceptibility testing]
    P, > Q[Implement treatment and biosecurity]

Vaccine Development

Autogenous Vaccines

Autogenous (inactivated) vaccines are prepared from bacterial isolates obtained from the affected farm. Formalin-killed whole-cell bacterins are the most common formulation [35]. These vaccines are administered by intraperitoneal injection or immersion. Efficacy is variable and often serotype-specific. For S. agalactiae, autogenous vaccines have shown protection in tilapia under laboratory conditions but field efficacy may be lower due to antigenic diversity [36]. Adjuvants such as mineral oil or aluminum hydroxide are used to enhance the immune response [37].

Recombinant and Subunit Vaccines

Recombinant proteins based on conserved surface antigens have been evaluated. The surface immunogenic protein (Sip) of S. agalactiae induces protective immunity in tilapia [38]. Similarly, the enolase (Eno) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of S. iniae are immunogenic and confer partial protection [39]. DNA vaccines encoding these antigens have also been tested but require optimization of delivery methods [40].

Live-Attenuated Vaccines

Attenuated strains of S. iniae and S. agalactiae have been developed through chemical mutagenesis or targeted gene deletion. A S. iniae mutant lacking the sagA gene (streptolysin S) is avirulent and provides protection against wild-type challenge in hybrid striped bass [41]. For S. agalactiae, deletion of the cpsE gene (capsular polysaccharide synthesis) yields a live vaccine that protects tilapia [42]. However, safety concerns regarding reversion to virulence and environmental shedding limit their commercial use.

Autogenous Vaccine Production and Use

The process for autogenous vaccine development involves:

  1. Isolation and identification of the causative Streptococcus species from diseased fish.
  2. Confirmation by PCR and serotyping.
  3. Large-scale culture in tryptic soy broth or brain heart infusion broth.
  4. Inactivation with 0.5% formalin at 4°C for 48 hours.
  5. Quality control: sterility testing, safety testing in a small fish group, and potency testing (antibody response).
  6. Formulation with adjuvant and administration via injection (0.1 mL per fish) or bath immersion (1:10 dilution for 30 minutes) [43].

Autogenous vaccines are particularly useful for farms with recurrent outbreaks caused by a specific serotype. Regulatory approval varies by jurisdiction; in many countries, they are exempt from full licensing if used on the farm of origin [44].

Challenges and Future Directions

Major challenges in vaccine development include:

  • Serotype diversity: S. agalactiae has multiple serotypes (Ia, Ib, II, III) with limited cross-protection [45].
  • Immune memory in fish: Teleosts have a slower adaptive response; booster vaccinations are often required [46].
  • Delivery methods: Injection is labor-intensive; immersion and oral vaccines are less immunogenic [47].
  • Antimicrobial resistance: Overuse of antibiotics has led to resistance in S. iniae and S. agalactiae, increasing the need for effective vaccines [48].

Future strategies include multivalent vaccines combining antigens from multiple serotypes, nanoparticle-based delivery systems, and reverse vaccinology approaches using genomic data [49, 50]. The use of bioinformatics to predict B-cell and T-cell epitopes is an emerging field, as discussed in the article on Biological Foundation Models for Veterinary Virology.

Conclusion

Streptococcosis remains a significant threat to global aquaculture, particularly in tilapia and trout farming. Understanding the molecular pathogenesis of S. iniae and S. agalactiae is essential for developing effective diagnostic tools and vaccines. Culture and PCR remain the mainstays of diagnosis, while autogenous vaccines offer a practical control measure for individual farms. Continued research into recombinant and live-attenuated vaccines, combined with improved delivery systems, will be critical for sustainable disease management.

References

[1] Austin B, Austin DA. Bacterial Fish Pathogens: Disease of Farmed and Wild Fish. 6th ed. Springer; 2016.

[2] Evans JJ, Klesius PH, Shoemaker CA. Streptococcus agalactiae in tilapia: an emerging pathogen. J Fish Dis. 2008;31(8):563-574.

[3] Locke JB, Colvin KM, Varki N, et al. Streptococcus iniae capsule impairs phagocytic clearance and contributes to virulence in fish. J Bacteriol. 2007;189(4):1279-1287.

[4] Brochet M, Couvé E, Zouine M, et al. Genomic diversity of Streptococcus agalactiae: identification of a new serotype. Microbiology. 2006;152(Pt 8):2313-2324.

[5] Lowe BA, Miller JD, Neely MN. Analysis of the polysaccharide capsule of the systemic pathogen Streptococcus iniae and its implications for virulence. Infect Immun. 2007;75(3):1246-1253.

[6] Fuller JD, Camus AC, Duncan CL, et al. Identification of a streptolysin S-associated gene cluster and its role in the pathogenesis of Streptococcus iniae disease. Infect Immun. 2002;70(10):5730-5739.

[7] Chmouryguina I, Suvorov A, Ferretti JJ, et al. Conservation of the C5a peptidase genes in group A and B streptococci. Infect Immun. 1996;64(7):2387-2390.

[8] Baiano JC, Barnes AC. Towards control of Streptococcus iniae. Fish Shellfish Immunol. 2009;26(5):693-700.

[9] Hynes WL, Walton SL. Hyaluronidases of Gram-positive bacteria. FEMS Microbiol Lett. 2000;183(2):201-207.

[10] Poyart C, Pellegrini E, Gaillot O, et al. Contribution of Mn-cofactored superoxide dismutase (SodA) to the virulence of Streptococcus agalactiae. Infect Immun. 2001;69(8):5098-5106.

[11] Rosini R, Rinaudo CD, Soriani M, et al. Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol Microbiol. 2006;61(1):126-141.

[12] Milani CJ, Aziz RK, Locke JB, et al. The novel polysaccharide deacetylase PgdA contributes to the virulence of Streptococcus iniae. Infect Immun. 2010;78(3):1065-1074.

[13] Mian GF, Godoy DT, Leal CA, et al. Aspects of the natural history of Streptococcus agalactiae infection in Nile tilapia. J Fish Dis. 2009;32(11):943-951.

[14] Kim KS. Pathogenesis of bacterial meningitis: from bacteraemia to neuronal injury. Nat Rev Neurosci. 2003;4(5):376-385.

[15] Delannoy CM, Crumlish M, Fontaine MC, et al. Human Streptococcus agalactiae strains in aquatic mammals and fish. BMC Microbiol. 2013;13:41.

[16] Zlotkin A, Chilmonczyk S, Eyngor M, et al. Trojan horse effect: phagocyte-mediated Streptococcus iniae infection of fish. Infect Immun. 2003;71(5):2318-2325.

[17] Wang KY, Huang JL, Chen DF, et al. Immune response of tilapia (Oreochromis niloticus) to Streptococcus agalactiae infection. Fish Shellfish Immunol. 2012;33(4):1006-1012.

[18] Eldar A, Bejerano Y, Livoff A, et al. Experimental streptococcal meningo-encephalitis in cultured fish. Vet Microbiol. 1995;43(1):33-40.

[19] Chang PH, Plumb JA. Histopathology of experimental Streptococcus sp. infection in tilapia, Oreochromis niloticus. J Fish Dis. 1996;19(2):131-139.

[20] Shoemaker CA, Klesius PH, Evans JJ. Prevalence of Streptococcus iniae in tilapia, hybrid striped bass, and channel catfish on commercial fish farms in the United States. Am J Vet Res. 2001;62(2):174-177.

[21] Perera RP, Johnson SK, Lewis DH. Epizootiological aspects of Streptococcus iniae affecting tilapia in Texas. Aquaculture. 1997;152(1-4):25-33.

[22] Rodkhum C, Kayansamruaj P, Pirarat N, et al. Effect of water temperature on susceptibility to Streptococcus agalactiae serotype Ia infection in Nile tilapia (Oreochromis niloticus). J Fish Dis. 2011;34(12):903-910.

[23] Buller NB. Bacteria and Fungi from Fish and Other Aquatic Animals: A Practical Identification Manual. 2nd ed. CABI; 2014.

[24] Vandamme P, Devriese LA, Pot B, et al. Streptococcus difficile is a nonhemolytic group B, type Ib Streptococcus. Int J Syst Bacteriol. 1997;47(1):81-85.

[25] Mata AI, Gibello A, Casamayor A, et al. Multiplex PCR assay for detection of bacterial pathogens associated with warm-water streptococcosis in fish. Appl Environ Microbiol. 2004;70(5):3183-3187.

[26] Berridge BR, Fuller JD, de Azavedo J, et al. Development of specific nested oligonucleotide PCR primers for the Streptococcus iniae 16S-23S ribosomal DNA intergenic spacer. J Clin Microbiol. 1998;36(9):2778-2781.

[27] Matsuyama T, Kamaishi T, Oseko N, et al. A PCR method for detection of Streptococcus iniae in fish. Fish Pathol. 2006;41(3):115-120.

[28] Hassan AA, Abdulmawjood A, Yildirim AO, et al. Identification of Streptococcus agalactiae by PCR targeting the cfb gene. Vet Microbiol. 2001;80(3):243-250.

[29] Evans JJ, Klesius PH, Shoemaker CA, et al. Identification and epidemiology of Streptococcus agalactiae from tilapia. J Fish Dis. 2006;29(8):469-478.

[30] Jiménez A, Tibaquirá V, Rojas M, et al. Multiplex PCR for simultaneous detection of Streptococcus agalactiae, Streptococcus iniae and Lactococcus garvieae in fish. J Microbiol Methods. 2011;87(1):98-102.

[31] Keeling SE, Brosnahan CL, Johnston C, et al. Development and validation of a real-time PCR assay for the detection of Streptococcus agalactiae in fish. J Fish Dis. 2013;36(7):635-643.

[32] Suebsing R, Kampeera J, Tookdee B, et al. Evaluation of colorimetric loop-mediated isothermal amplification assay for visual detection of Streptococcus agalactiae and Streptococcus iniae in tilapia. Lett Appl Microbiol. 2013;57(4):317-324.

[33] Pasnik DJ, Evans JJ, Klesius PH. Duration of protective antibodies and site of antigen uptake in Nile tilapia immunized with Streptococcus agalactiae bacterin. Fish Shellfish Immunol. 2006;20(4):582-590.

[34] Klesius PH, Evans JJ, Shoemaker CA, et al. A rapid antigen-capture ELISA for the detection of Streptococcus agalactiae in fish. J Aquat Anim Health. 2006;18(4):259-265.

[35] Eldar A, Horovitcz A, Bercovier H. Development and efficacy of a vaccine against Streptococcus iniae infection in farmed rainbow trout. Vet Immunol Immunopathol. 1997;56(1-2):175-183.

[36] Evans JJ, Klesius PH, Shoemaker CA. Efficacy of Streptococcus agalactiae (group B) vaccine in tilapia (Oreochromis niloticus) by intraperitoneal and bath immersion administration. Vaccine. 2004;22(27-28):3769-3773.

[37] Anderson DP. Adjuvants and immunostimulants for enhancing vaccine potency in fish. Dev Biol Stand. 1997;90:257-265.

[38] Pasnik DJ, Evans JJ, Klesius PH. A recombinant Sip protein vaccine against Streptococcus agalactiae in Nile tilapia. Vaccine. 2005;23(46-47):5296-5302.

[39] Zhang D, Li A, Guo Y, et al. Immunogenicity and protective efficacy of recombinant enolase and GAPDH of Streptococcus iniae in Nile tilapia. Fish Shellfish Immunol. 2015;47(1):456-462.

[40] Sun Y, Liu CS, Sun L. A multivalent DNA vaccine encoding the GAPDH and enolase genes of Streptococcus iniae confers protection in turbot. Vaccine. 2011;29(47):8571-8578.

[41] Locke JB, Aziz RK, Vicknair MR, et al. Streptococcus iniae M-like protein contributes to virulence in fish and is a target for live attenuated vaccine development. PLoS One. 2008;3(7):e2824.

[42] Li Y, Liu Y, Zhou Z, et al. A live attenuated vaccine for Streptococcus agalactiae in tilapia. Fish Shellfish Immunol. 2016;58:123-130.

[43] Gudding R, Lillehaug A, Evensen Ø. Recent developments in fish vaccinology. Vet Immunol Immunopathol. 1999;72(1-2):203-212.

[44] Brudeseth BE, Wiulsrød R, Fredriksen BN, et al. Status and future perspectives of vaccines for industrialised fin-fish farming. Fish Shellfish Immunol. 2013;35(6):1759-1768.

[45] Martins ER, Melo-Cristino J, Ramirez M. Evidence for rare capsular switching in Streptococcus agalactiae. J Bacteriol. 2010;192(5):1361-1369.

[46] Ellis AE. Innate host defense mechanisms of fish against viruses and bacteria. Dev Comp Immunol. 2001;25(8-9):827-839.

[47] Vinitnantharat S, Gravningen K, Greger E. Fish vaccines. Adv Vet Med. 1999;41:539-550.

[48] Akinbowale OL, Peng H, Barton MD. Antimicrobial resistance in bacteria isolated from aquaculture sources in Australia. J Appl Microbiol. 2006;100(5):1103-1113.

[49] Ma J, Bruce TJ, Jones EM, et al. A review of fish vaccine development strategies: conventional methods and modern biotechnological approaches. Microorganisms. 2019;7(11):569.

[50] Dhar AK, Manna SK, Thomas Allnutt FC. Viral vaccines for farmed finfish. Virus Dis. 2014;25(1):1-17.